Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
Thales Kronenberger, Stefan Laufer, Thanigaimalai Pillaiyar
Drug Discovery Today (2023) Vol. 28, Iss. 6, pp. 103579-103579
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Nucleoside‐Based Drug Target with General Antimicrobial Screening and Specific Computational Studies against SARS‐CoV‐2 Main Protease
Sarkar M. A. Kawsar, Md. Ahad Hossain, Supriyo Saha, et al.
ChemistrySelect (2024) Vol. 9, Iss. 15
Closed Access | Times Cited: 25
GPCNDTA: Prediction of drug-target binding affinity through cross-attention networks augmented with graph features and pharmacophores
Li Zhang, Chun-Chun Wang, Zhang Yon, et al.
Computers in Biology and Medicine (2023) Vol. 166, pp. 107512-107512
Closed Access | Times Cited: 24
Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity
Jenny Desantis, Alessandro Bazzacco, Michela Eleuteri, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116202-116202
Open Access | Times Cited: 10
Indole Derivatives: A Versatile Scaffold in Modern Drug Discovery—An Updated Review on Their Multifaceted Therapeutic Applications (2020–2024)
Xingyou Mo, Devendra Pratap Rao, Kirandeep Kaur, et al.
Molecules (2024) Vol. 29, Iss. 19, pp. 4770-4770
Open Access | Times Cited: 8
Non-Canonical Amino Acids in Analyses of Protease Structure and Function
Peter Goettig, Nikolaj G. Koch, Nediljko Budiša
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14035-14035
Open Access | Times Cited: 16
On the origins of SARS-CoV-2 main protease inhibitors
Yves L. Janin
RSC Medicinal Chemistry (2023) Vol. 15, Iss. 1, pp. 81-118
Closed Access | Times Cited: 16
Design, Synthesis, X-ray Crystallography, and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease
Md Ashraf-Uz-Zaman, Teck Khiang Chua, Xin Li, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 2, pp. 715-731
Closed Access | Times Cited: 5
Improved fluorescence‐based assay for rapid screening and evaluation of SARS‐CoV‐2 main protease inhibitors
Rui Zhang, Haohao Yan, Jiahao Zhou, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 3
Closed Access | Times Cited: 5
Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions
Ahmed M. Shawky, Faisal A. Almalki, Hayat Ali Alzahrani, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116704-116704
Closed Access | Times Cited: 5
Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CLpro inhibitors
Feng Wang, Donglan Liu, Dingding Gao, et al.
International Journal of Biological Macromolecules (2024) Vol. 264, pp. 130377-130377
Closed Access | Times Cited: 4
A comprehensive investigation into the spectroscopic properties, solvent effects on electronic properties, structural characteristics, topological insights, reactive sites, and molecular docking of racecadotril: A potential antiviral and antiproliferative agent
R. Manjula, C. Pavithra, A. Ram Kumar, et al.
Journal of the Indian Chemical Society (2025), pp. 101702-101702
Closed Access
Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19
Fu-Mao Zhang, Ting Huang, Feng Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115721-115721
Closed Access | Times Cited: 12
Development of Fluorescence-Based Assays for Key Viral Proteins in the SARS-CoV-2 Infection Process and Lifecycle
Mingzhenlong Deng, Chuang Zhang, Wanli Yan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2850-2850
Open Access | Times Cited: 4
Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 variants bound to PF-07304814
Haihai Jiang, Xiaofang Zou, Pei Zeng, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 10
Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19
Gangireddy Navitha Reddy, Akanksha Jogvanshi, Sana Naikwadi, et al.
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 9, pp. 943-955
Closed Access | Times Cited: 8
Chrysin 7-O-β-D-glucuronide is not a potential inhibitor against SARS-CoV-2 main protease
Rui Zhang, Jiahao Zhou, Haohao Yan, et al.
International Journal of Antimicrobial Agents (2024) Vol. 63, Iss. 5, pp. 107136-107136
Closed Access | Times Cited: 2
Asymmetric imidazole-4,5-dicarboxamides derivatives as SARS-CoV-2 main protease inhibitors: Design, Synthesis and Biological Evaluation
P. Huynh, Phatcharin Khamplong, Minh-Hoang Phan, et al.
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 1
Synthesis and Evaluation of 9-Aminoacridines with SARS-CoV-2 Antiviral Activity
Thane Jones, Natalia Monakhova, Florence Guivel‐Benhassine, et al.
ACS Omega (2023) Vol. 8, Iss. 43, pp. 40817-40822
Open Access | Times Cited: 4
Synthesis, SARS-CoV-2 main protease inhibition, molecular docking and in silico ADME studies of furanochromene-quinoline hydrazone derivatives
Blake M. Shellenberger, Olivia N. Basile, Joel Cassel, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 102, pp. 129679-129679
Closed Access | Times Cited: 1
Transformation of peptides to small molecules in medicinal chemistry: Challenges and opportunities
Zeyu Han, Zekai Shen, Jiayue Pei, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4243-4265
Open Access | Times Cited: 1
Dimeric and monomeric conformation of SARS-CoV-2 main protease: New technical approaches based on IR radiation
Federica Piccirilli, Hendrik Vondracek, Lucia Silvestrini, et al.
Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy (2024) Vol. 322, pp. 124772-124772
Open Access | Times Cited: 1
Mechanistic Insights into the Mutational Landscape of the Main Protease/3CLPro and Its Impact on Long-Term COVID-19/SARS-CoV-2 Management
Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, Nonjabulo Ntombikhona Magwaza, et al.
(2024)
Open Access | Times Cited: 1
Molecular targets in SARS-CoV-2 infection: an update on repurposed drug candidates
Dibachehr Rahmani, Ameneh Jafari, Prashant Kesharwani, et al.
Pathology - Research and Practice (2024) Vol. 263, pp. 155589-155589
Closed Access | Times Cited: 1
Effects of SARS-CoV-2 Main Protease Mutations at Positions L50, E166, and L167 Rendering Resistance to Covalent and Noncovalent Inhibitors
Andrey Kovalevsky, Annie Aniana, Rodolfo Ghirlando, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 20, pp. 18478-18490
Closed Access | Times Cited: 1
Perspective for Drug Discovery Targeting SARS Coronavirus Methyltransferases: Function, Structure and Inhibition
Xin Li, Yongcheng Song
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 18642-18655
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top